COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

30,170 Articles (22,186 medRxiv, 7,984 bioRxiv)

Most recent first Previous |  Page 1354: Articles 13531-13540  | Next

Country-wide genomic surveillance of SARS-CoV-2 strains
Kalia, K., Saberwal, G., Sharma, G.
10.1101/2021.06.08.447365 — Posted: 2021-06-09 Discussion: Onsite
Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.
Moore, P., Moyo, T., Hermanus, T., Kgagudi, P., Ayres, F., Makhado, Z., Sadoff, J., Le Gars, M., van Roey, G., Crowther, C., Garrett, N., Bekker, L.-G., Morris, L., Schuitemaker, H., Gray, G.
10.1101/2021.06.09.447722 — Posted: 2021-06-09
Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine
Pitcovski, J., Gruzdev, N., Abzach, A., Katz, C., Ben-Adiva, R., Brand Schwartz, M., Yadid, I., Haviv, H., Rapoport, I., Bloch, I., Shadmon, R., Eitan, Z., Eliyahu, D., Hillel, T., Laster, M., Kremer Tal, S., Byk Tennenbaum, T., Shahar, E.
10.1101/2021.06.09.447656 — Posted: 2021-06-09
DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging
Sepe, S., Rossiello, F., Cancila, V., Iannelli, F., Matti, V., Cicio, G., Cabrini, M., Marinelli, E., Alabi, B., di Lillo, A., Di Napoli, A., Shay, J. W., Tripodo, C., d'Adda di Fagagna, F.
10.1101/2021.06.09.447484 — Posted: 2021-06-09 Discussion: Onsite | Offsite
Monitoring group activity of hamsters and mice as a novel tool to evaluate COVID-19 progression, convalescence and rVSV-ΔG-spike vaccination efficacy
Melamed, S., Politi, B., Grauer, E., Achdout, H., Aftalion, M., Gur, D., Tamir, H., Yahalom-Ronen, Y., Maimon, S., Yitzhak, E., Weiss, S., Rosner, A., Erez, N., Yitzhaki, S., Shapira, S. C., Paran, N., Mamroud, E., Vagima, Y., Israely, T.
10.1101/2021.06.09.447687 — Posted: 2021-06-09
The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour
Oliveira, A. S., Shoemark, D., Ibarra, A. A., Davidson, A. D., Berger, I., Schaffitzel, C., Mulholland, A. J.
10.1101/2021.06.07.447341 — Posted: 2021-06-09
Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics
Cao, W., Cho, C.-C. D., Geng, Z. Z., Ma, X. R., Allen, R., Shaabani, N., Vatansever, E. C., Alugubelli, Y. R., Ma, Y., Ellenburg, W. H., Yang, K. S., Qiao, Y., Ji, H., Xu, S., Liu, W. R.
10.1101/2021.06.08.447613 — Posted: 2021-06-09
Multi-color super-resolution imaging to study human coronavirus RNA during cellular infection
Wang, J., Han, M., Wang, H., Moeckl, L., Zeng, L., Moerner, W. E., Qi, L. S.
10.1101/2021.06.09.447760 — Posted: 2021-06-09
Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection
Halwe, S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M., Rohde, C., Kraehling, V., Gellhorn-Serra, M., Kreer, C., Kluever, M., Sauerhering, L., Schmidt, J., Cai, Z., Han, F., Young, D., Yang, G., Widera, M., Koch, M., Werner, A., Kaemper, L., Becker, N., Marlow, M. S., Eickmann, M., Ciesek, S., Schiele, F., Klein, F., Becker, S.
10.1101/2021.06.09.447662 — Posted: 2021-06-09
Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants
Logue, J., Johnson, R., Patel, N., Zhou, B., Maciejewski, S., Zhou, H., Portnoff, A., Tian, J.-H., McGrath, M., Haupt, R., Weston, S., Hammod, H., Guebre-Xabier, M., Dillen, C., Plested, J., Cloney-Clark, S., Greene, A., Massare, M., Glenn, G., Smith, G., Frieman, M.
10.1101/2021.06.08.447631 — Posted: 2021-06-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).